USRE44779E1
(en)
|
1997-03-07 |
2014-02-25 |
Santaris Pharma A/S |
Bicyclonucleoside and oligonucleotide analogues
|
AU2003225495B2
(en)
|
2002-04-05 |
2009-01-15 |
Roche Innovation Center Copenhagen A/S |
Oligomeric compounds for the modulation HIF-1alpha expression
|
DK1569661T3
(da)
|
2002-11-18 |
2010-01-11 |
Santaris Pharma As |
Antisense design
|
US7713738B2
(en)
|
2003-02-10 |
2010-05-11 |
Enzon Pharmaceuticals, Inc. |
Oligomeric compounds for the modulation of survivin expression
|
ES2576677T3
(es)
|
2003-03-21 |
2016-07-08 |
Roche Innovation Center Copenhagen A/S |
Análogos de ARN interfirientes cortos
|
EP1706489B9
(de)
|
2003-12-23 |
2011-01-05 |
Santaris Pharma A/S |
Oligomere verbindungen zur modulation von bcl-2
|
ATE476441T1
(de)
|
2004-11-09 |
2010-08-15 |
Santaris Pharma As |
Wirksame lna-oligonukleotide zur inhibierung von hif-1a
|
US9447138B2
(en)
|
2004-11-09 |
2016-09-20 |
Roche Innovation Center Copenhagen A/S |
Potent LNA oligonucleotides for the inhibition of HIF-1a expression
|
KR20070095882A
(ko)
|
2004-11-09 |
2007-10-01 |
산타리스 팔마 에이/에스 |
Lna 올리고뉴클레오티드 및 암의 치료
|
US8071306B2
(en)
|
2005-01-25 |
2011-12-06 |
Merck Sharp & Dohme Corp. |
Methods for quantitating small RNA molecules
|
AU2007229161B2
(en)
|
2006-03-23 |
2012-07-12 |
Roche Innovation Center Copenhagen A/S |
Small internally segmented interfering RNA
|
CA2649045C
(en)
|
2006-04-03 |
2019-06-11 |
Santaris Pharma A/S |
Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
|
SG10201406016SA
(en)
|
2006-04-03 |
2014-11-27 |
Stella Aps |
Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
|
EP2054415A1
(de)
*
|
2006-07-14 |
2009-05-06 |
Santaris Pharma A/S |
Adenosinrezeptorantagonisten
|
CA2681406A1
(en)
|
2007-03-22 |
2008-09-25 |
Santaris Pharma A/S |
Rna antagonist compounds for the inhibition of apo-b100 expression
|
WO2008113832A2
(en)
|
2007-03-22 |
2008-09-25 |
Santaris Pharma A/S |
SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF TARGET mRNA
|
ES2798758T3
(es)
|
2007-06-06 |
2020-12-14 |
Sarepta Therapeutics Inc |
Proteínas variantes de empalme her2 y her3 solubles, oligonucleótidos de cambio de empalme y su uso en el tratamiento de enfermedades
|
WO2009027978A1
(en)
|
2007-08-30 |
2009-03-05 |
Hadasit Medical Research Services & Development Ltd. |
NUCLEIC ACID SEQUENCES COMPRISING NF-ϰB BINDING SITE WITHIN O(6)-METHYLGUANINE-DNA-METHYLTRANSFERASE (MGMT) PROMOTER REGION AND USES THEREOF FOR THE TREATMENT OF CANCER AND IMMUNE-RELATED DISORDERS
|
EP2548962B1
(de)
|
2007-09-19 |
2016-01-13 |
Applied Biosystems, LLC |
Sirna-sequenz-unabhängige Modifikationsformate zur Verringerung von das Ziel verfehlenden phänotypischen Effekten bei RNAI und stabilisierte Formen davon
|
EP3492594A1
(de)
|
2007-10-04 |
2019-06-05 |
Roche Innovation Center Copenhagen A/S |
Mikro-mirs
|
AU2009221064B2
(en)
|
2008-03-07 |
2014-12-11 |
Roche Innovation Center Copenhagen A/S |
Pharmaceutical compositions for treatment of microRNA related diseases
|
WO2010012667A1
(en)
|
2008-08-01 |
2010-02-04 |
Santaris Pharma A/S |
Micro-rna mediated modulation of colony stimulating factors
|
ES2599979T3
(es)
|
2009-04-24 |
2017-02-06 |
Roche Innovation Center Copenhagen A/S |
Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón
|
US8563528B2
(en)
|
2009-07-21 |
2013-10-22 |
Santaris Pharma A/S |
Antisense oligomers targeting PCSK9
|
WO2011105902A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 8-beta (c8-beta) and uses thereof
|
WO2011105900A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
|
WO2011105901A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 9 (c9) and uses thereof
|
WO2011108930A1
(en)
|
2010-03-04 |
2011-09-09 |
Interna Technologies Bv |
A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS DIAGNOSTIC AND THERAPEUTIC USES IN DISEASES OR CONDITIONS ASSOCIATED WITH EMT
|
CA2804599C
(en)
|
2010-07-06 |
2023-01-31 |
Interna Technologies Bv |
Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
|
GB201012418D0
(en)
|
2010-07-23 |
2010-09-08 |
Santaris Pharma As |
Process
|
EP2474617A1
(de)
|
2011-01-11 |
2012-07-11 |
InteRNA Technologies BV |
MIR zur Behandlung von Neoangiogenese
|
EP3578572A1
(de)
*
|
2011-07-21 |
2019-12-11 |
Rhodia Operations |
Guar-hydroxypropyltrimethylammonium-chlor und verwendungen davon für haarbehandlungszusammensetzungen
|
US10174314B2
(en)
|
2011-12-22 |
2019-01-08 |
Interna Technologies B.V. |
MiRNA for treating head and neck cancer
|
MX356509B
(es)
|
2011-12-22 |
2018-05-30 |
Alios Biopharma Inc |
Nucleósidos sustituidos, nucleótidos y análogos de los mismos.
|
USRE48171E1
(en)
|
2012-03-21 |
2020-08-25 |
Janssen Biopharma, Inc. |
Substituted nucleosides, nucleotides and analogs thereof
|
US9441007B2
(en)
|
2012-03-21 |
2016-09-13 |
Alios Biopharma, Inc. |
Substituted nucleosides, nucleotides and analogs thereof
|
EP3800256A1
(de)
|
2012-11-06 |
2021-04-07 |
InteRNA Technologies B.V. |
Kombination zur therapeutischen verwendung bei krankheiten oder zuständen im zusammenhang mit melanomen oder bei krankheiten oder zuständen im zusammenhang mit dem aktivierten b-raf-signalweg
|
WO2014108759A1
(en)
|
2013-01-14 |
2014-07-17 |
Pierfrancesco Tassone |
INHIBITORS OF miRNAs 221 AND 222 FOR ANTI-TUMOR ACTIVITY IN MULTIPLE MYELOMA
|
WO2014144844A1
(en)
|
2013-03-15 |
2014-09-18 |
The Board Of Trustees Of The Leland Stanford Junior University |
tRNA DERIVED SMALL RNAs (tsRNAs) INVOLVED IN CELL VIABILITY
|
ES2770667T3
(es)
|
2013-06-27 |
2020-07-02 |
Roche Innovation Ct Copenhagen As |
Oligómeros antisentido y conjugados que se dirigen a PCSK9
|
GB201410693D0
(en)
|
2014-06-16 |
2014-07-30 |
Univ Southampton |
Splicing modulation
|
AU2015327836B2
(en)
|
2014-10-03 |
2021-07-01 |
Cold Spring Harbor Laboratory |
Targeted augmentation of nuclear gene output
|
CA2976688A1
(en)
|
2015-02-15 |
2016-08-18 |
Ribo Task Aps |
Acyl-amino-lna and/or hydrocarbyl-amino-lna oligonucleotides
|
TW201718618A
(zh)
*
|
2015-09-18 |
2017-06-01 |
田邊三菱製藥股份有限公司 |
架橋型核酸GuNA,其製造方法,及中間體化合物
|
KR20220105174A
(ko)
|
2015-10-09 |
2022-07-26 |
유니버시티 오브 사우스앰톤 |
유전자 발현의 조절 및 탈조절된 단백질 발현의 스크리닝
|
EP3933041B1
(de)
|
2015-12-14 |
2024-01-31 |
Cold Spring Harbor Laboratory |
Antisense-oligomere zur behandlung von autosomaldominierender geistiger behinderung
|
US11096956B2
(en)
|
2015-12-14 |
2021-08-24 |
Stoke Therapeutics, Inc. |
Antisense oligomers and uses thereof
|
EP3449002A4
(de)
|
2016-04-29 |
2019-09-25 |
Nanyang Technological University |
G-quadruplex-haltige antisense-oligonukleotide
|
US20220354888A1
(en)
|
2016-08-03 |
2022-11-10 |
Aalborg Universitet |
ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS
|
CN111278991B
(zh)
|
2017-08-25 |
2022-04-01 |
斯托克制药公司 |
用于治疗病况和疾病的反义寡聚体
|
US11497762B2
(en)
|
2017-11-03 |
2022-11-15 |
Interna Technologies B.V. |
MiRNA molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation
|
CA3088321A1
(en)
|
2018-02-12 |
2019-08-15 |
Interna Technologies B.V. |
Anticancer microrna and lipid formulations thereof
|
IT201900017234A1
(it)
|
2019-09-25 |
2021-03-25 |
Int Centre For Genetic Engineering And Biotechnology |
Anti-miRNA per il trattamento del leiomioma
|
CA3173647A1
(en)
|
2020-05-11 |
2021-11-18 |
Isabel AZNAREZ |
Opa1 antisense oligomers for treatment of conditions and diseases
|
IL304956A
(en)
|
2021-02-12 |
2023-10-01 |
Merand Pharmaceuticals Inc |
Materials, compositions and methods for treating hypoxia and ischemia-related disorders
|
CA3213391A1
(en)
|
2021-03-26 |
2022-09-29 |
Markus Sakari Kauppinen |
Microrna-134 inhibitors
|
KR20230170691A
(ko)
|
2021-03-26 |
2023-12-19 |
뉴미르나 테라퓨틱스 에이피에스 |
MicroRNA-27b 억제제들
|
WO2022254021A1
(en)
|
2021-06-04 |
2022-12-08 |
Neumirna Therapeutics Aps |
Antisense oligonucleotides targeting adenosine kinase
|
CA3229568A1
(en)
|
2021-08-17 |
2023-02-23 |
Korea Advanced Institute Of Science And Technology |
Antisense oligonucleotide targeting cav3.1 gene and uses thereof
|
EP4388096A1
(de)
|
2021-08-19 |
2024-06-26 |
Neumirna Therapeutics ApS |
Antisense oligonukleotide gegen adenosinkinase
|
EP4332239A1
(de)
|
2022-08-30 |
2024-03-06 |
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l. |
Mir-basierter test zur diagnose und prognose von gastro-entero-pankreatischen neuroendokrinen tumoren
|